TransMedics Group, Inc. (NASDAQ:TMDX) Stock Has Average Price Target of $121.10 According to Brokerages

Key Points

• Analyst sentiment is mixed: TransMedics Group has a consensus “Hold” rating from 12 analysts, with five buys, six holds and one sell. The average 12-month price target is $121.10, above the stock’s reported price of $79.79.
• Quarterly results were mixed: TransMedics reported $189.95 million in revenue, up 20.7% year over year and ahead of estimates, but earnings per share of $0.44 missed the $0.50 consensus forecast.
• Investor ownership remains strong: Institutional investors own 99.67% of the company, while Director David Weill increased his holdings by 8.87% through a purchase of 1,336 shares at an average price of $81.63.

Shares of TransMedics Group, Inc. (NASDAQ:TMDX - Get Free Report) have been assigned a consensus rating of "Hold" from the twelve ratings firms that are presently covering the firm, MarketBeat reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation and five have assigned a buy recommendation to the company. The average 12 month price target among brokers that have covered the stock in the last year is $121.10.

Several equities research analysts have weighed in on TMDX shares. Canaccord Genuity Group reissued a "buy" rating and set a $124.00 price target on shares of TransMedics Group in a research report on Tuesday, June 30th. TD Cowen restated a "buy" rating and issued a $120.00 price objective on shares of TransMedics Group in a research report on Tuesday, September 8th. Stifel Nicolaus upped their price objective on shares of TransMedics Group from $75.00 to $80.00 and gave the company a "hold" rating in a research note on Thursday, June 18th. UBS Group dropped their target price on shares of TransMedics Group from $80.00 to $77.00 and set a "neutral" rating for the company in a report on Wednesday, August 5th. Finally, Piper Sandler reissued an "overweight" rating and issued a $100.00 target price (down from $120.00) on shares of TransMedics Group in a research note on Wednesday, August 5th.

Insider Buying and Selling at TransMedics Group

In other TransMedics Group news, Director David Weill bought 1,336 shares of TransMedics Group stock in a transaction dated Friday, September 11th. The shares were purchased at an average cost of $81.63 per share, with a total value of $109,057.68. Following the completion of the purchase, the director owned 16,392 shares of the company's stock, valued at approximately $1,338,078.96. This represents a 8.87% increase in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. Corporate insiders own 6.90% of the company's stock.

Institutional Trading of TransMedics Group

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the business. Envestnet Portfolio Solutions Inc. increased its position in TransMedics Group by 77.3% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 7,691 shares of the company's stock valued at $511,000 after purchasing an additional 3,352 shares during the period. WINTON GROUP Ltd raised its holdings in TransMedics Group by 52.4% in the 2nd quarter. WINTON GROUP Ltd now owns 18,203 shares of the company's stock worth $1,209,000 after purchasing an additional 6,262 shares in the last quarter. Integrated Wealth Concepts LLC lifted its position in shares of TransMedics Group by 31.3% in the 2nd quarter. Integrated Wealth Concepts LLC now owns 2,877 shares of the company's stock worth $191,000 after purchasing an additional 686 shares during the period. IFP Advisors Inc lifted its position in shares of TransMedics Group by 4.8% in the 2nd quarter. IFP Advisors Inc now owns 4,652 shares of the company's stock worth $309,000 after purchasing an additional 213 shares during the period. Finally, Corient Private Wealth LP lifted its position in shares of TransMedics Group by 123.2% in the 2nd quarter. Corient Private Wealth LP now owns 19,285 shares of the company's stock worth $1,281,000 after purchasing an additional 10,644 shares during the period. Hedge funds and other institutional investors own 99.67% of the company's stock.

TransMedics Group Stock Down 0.0%

TMDX opened at $79.79 on Monday. TransMedics Group has a 12 month low of $60.10 and a 12 month high of $156.00. The company has a current ratio of 6.62, a quick ratio of 6.07 and a debt-to-equity ratio of 1.62. The business's 50-day moving average price is $85.61 and its 200-day moving average price is $84.97. The company has a market cap of $2.76 billion, a P/E ratio of 20.51, a P/E/G ratio of 1.10 and a beta of 1.94.

TransMedics Group (NASDAQ:TMDX - Get Free Report) last issued its earnings results on Tuesday, August 4th. The company reported $0.44 earnings per share for the quarter, missing the consensus estimate of $0.50 by ($0.06). The company had revenue of $189.95 million for the quarter, compared to analysts' expectations of $184.00 million. TransMedics Group had a net margin of 22.69% and a return on equity of 15.88%. The company's revenue was up 20.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.92 earnings per share. On average, equities analysts expect that TransMedics Group will post 1.46 EPS for the current year.

TransMedics Group Company Profile

TransMedics Group, Inc is a medical technology company that develops organ transplant systems designed to preserve and assess donated organs outside the body before transplantation. Its primary platform, the Organ Care System (OCS), uses warm perfusion technology to circulate oxygenated blood and nutrients through organs, helping maintain organ function during transport and potentially expanding the pool of organs available for transplant.

The company offers OCS solutions for heart, lung and liver transplantation.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.